The nexus of chronic kidney disease (CKD) and cardiovascular disease (CVD) amplifies the
morbidity and mortality of CKD, emphasizing the need for defining and establishing …

Fibroblast growth factor 23 (FGF23) and Klotho play key roles, along with serum phosphate
and parathyroid hormone (PTH), in disordered mineral metabolism in chronic kidney …

Three members of the fibroblast growth factor (FGF) family, FGF19, FGF21 and FGF23, are
different from the other members in two major aspects. First, they are actually not growth …

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease
(CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral …

The recent successful demonstrations that the nonsteroidal mineralocorticoid receptor (MR)
antagonist finerenone provides effective kidney and cardiovascular (CV) protection in …

FGF23 and Klotho in chronic kidney disease : Current Opinion in Nephrology and
Hypertension FGF23 and Klotho in chronic kidney disease : Current Opinion in Nephrology …

The discovery of fibroblast growth factor‐23 (FGF 23) and its co‐receptor α‐klotho has
broadened our understanding of mineral metabolism and led to a renewed research focus …

The well-established increased cardiovascular risk that is a hallmark of chronic kidney
disease (CKD) has directed research to metabolic changes that are typical of CKD …

Background: Membrane αKlotho (hereinafter called Klotho) is highly expressed in the kidney
and functions as a coreceptor of FGF receptors (FGFRs) to activate specific fibroblast growth …

Disordered phosphate homeostasis is thought to contribute mechanistically to the high rates
of cardiovascular disease encountered in patients with chronic kidney disease (CKD), but …